NCT04365933View on ClinicalTrials.gov

A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 25, 2020

Primary Completion Date

June 16, 2021

Study Completion Date

November 29, 2021

Conditions
Hepatitis B, Chronic
Interventions
DRUG

EYP001a

Oral tablets

DRUG

Entecavir

Oral tablets

DRUG

Pegylated interferon alpha2a

Subcutaneous

Trial Locations (6)

Unknown

ENYO PHARMA Investigative site HK01, Hong Kong

ENYO PHARMA Investigative site KR01, Busan

ENYO PHARMA Investigative site TW03, Kaohsiung City

ENYO PHARMA Investigative site TW04, Kaohsiung City

ENYO PHARMA Investigative site TW01, Taipei

ENYO PHARMA Investigative site TW02, Taoyuan District

Sponsors

Lead Sponsor

Enyo Pharma
All Listed Sponsors
lead

Enyo Pharma

INDUSTRY

NCT04365933 - A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir | Biotech Hunter | Biotech Hunter